Haptoglobin and haptoglobin genotypes in diabetes: A silver bullet to identify the responders to antioxidant therapy?

Abstract

Get full access to this article

View all access options for this article.

References

Raynes

Eagling

McAdam

. Acute-phase protein synthesis in human hepatoma cells: Differential regulation of serum amyloid A (SAA) and haptoglobin by interleukin-1 and interleukin-6. Clin Exp Immunol 1991; 83: 488–491.

Murray

Connell

Pert

. The role of haptoglobin in the clearance and distribution of extracorpuscular hemoglobin. Blood 1961; 17: 45–53.

Kristiansen

Graversen

Jacobsen

et al.

Identification of the haemoglobin scavenger receptor. Nature 2001; 409: 198–201.

Bowman

Kurosky

. Haptoglobin. The evolutionary product of duplication, unequal crossing over, and point mutation. Adv Hum Genet 1982; 12: 189–261.

Langlois

Delanghe

. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 1996; 42: 1589–1600.

Levy

Hochberg

Jablonski

et al.

Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The Strong Heart Study. J Am Coll Cardiol 2002; 40: 1984–1990.

Roguin

Koch

Kastrati

et al.

Haptoglobin genotype is predictive of major adverse cardiac events in the 1-year period after percutaneous transluminal coronary angioplasty in individuals with diabetes. Diabetes Care 2003; 26: 2628–2631.

Suleiman

Aronson

Asleh

et al.

Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction. Diabetes 2005; 54: 2802–2806.

Zafrir

Azencot

Dobrecky-Mery

et al.

Resting heart rate and measures of effort-related cardiac autonomic dysfunction predict cardiovascular events in asymptomatic type 2 diabetes. Eur J Prev Cardiol 2016; 23: 1298–1306.

10.

Vardi

Blum

Levy

. Haptoglobin genotype and cardiovascular outcomes in diabetes mellitus – natural history of the disease and the effect of vitamin E treatment. Meta-analysis of the medical literature. Eur J Intern Med 2012; 23: 628–632.

11.

Dalan

Liuh Ling

. The protean role of haptoglobin and haptoglobin genotypes on vascular complications in diabetes mellitus. Eur J Prev Cardiol. 2018; 25: 1502–1519.

12.

Adams

Cox

Freedman

et al.

Genetic analysis of haptoglobin polymorphisms with cardiovascular disease and type 2 diabetes in the Diabetes Heart Study. Cardiovasc Diabetol 2013; 12: 31–31.

13.

Shi

et al.

The association of haptoglobin gene variants and retinopathy in type 2 diabetic patients: A meta-analysis. J Diabetes Res 2017; 2017: 2195059–2195059.

14.

Chen

et al.

Circulating tocopherols and risk of coronary artery disease: A systematic review and meta-analysis. Eur J Prev Cardiol 2016; 23: 748–757.

15.

Burton

Cheng

Webb

et al.

Vitamin E in young and old human red blood cells. Biochim Biophys Acta 1986; 860: 84–90.

16.

Fahrenholtz

Doleiden

Trozzolo

et al.

On the quenching of singlet oxygen by alpha-tocopherol. Photochem Photobiol 1974; 20: 505–509.

17.

Levy

Blum

. Pharmacogenomics in prevention of diabetic cardiovascular disease: Utilization of the haptoglobin genotype in determining benefit from vitamin E. Expert Rev Cardiovasc Ther 2007; 5: 1105–1111.

18.

Virtamo

Rapola

Ripatti

et al.

Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease. Arch Intern Med 1998; 158: 668–675.

19.

De Gaetano

. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: A randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001; 357: 89–95.

20.

Sacco

Pellegrini

Roncaglioni

et al.

Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003; 26: 3264–3272.

21.

Lee

Cook

Gaziano

et al.

Vitamin E in the primary prevention of cardiovascular disease and cancer: The Women’s Health Study: A randomized controlled trial. JAMA 2005; 294: 56–65.

22.

Sesso

Buring

Christen

et al.

Vitamins E and C in the prevention of cardiovascular disease in men: The Physicians’ Health Study II randomized controlled trial. JAMA 2008; 300: 2123–2133.

23.

Stephens

Parsons

Schofield

et al.

Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 347: 781–786.

24.

Yusuf

Dagenais

Pogue

et al.

Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 154–160.

25.

Lonn

Yusuf

Hoogwerf

et al.

Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: Results of the HOPE study and MICRO-HOPE substudy. Diabetes Care 2002; 25: 1919–1927.

26.

Mann

Lonn

et al.

Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: Results of the HOPE study. Kidney Int 2004; 65: 1375–1380.

27.

Lonn

Bosch

Yusuf

et al.

Effects of long-term vitamin E supplementation on cardiovascular events and cancer: A randomized controlled trial. JAMA 2005; 293: 1338–1347.

28.

Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360: 23–33.

29.

Boaz

Smetana

Weinstein

et al.

Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): Randomised placebo-controlled trial. Lancet 2000; 356: 1213–1218.

30.

Milman

Blum

Shapira

et al.

Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: A prospective double-blinded clinical trial. Arterioscler Thromb Vasc Biol 2008; 28: 341–347.